Earlier this year, the FDA approved the same vaccine for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
It is the first and only cell-based quadrivalent influenza vaccine in the United States and is an alternative for individuals allergic to the egg-based vaccines.
